Novo Nordisk, a leading pharmaceutical company, has announced that it will be maintaining its popular insulin brand, Mixtard, in vial form in the Indian market, even as it phases out Penfill cartridges. This move comes in response to worries surrounding the discontinuation of commonly used insulin products. The decision is part of the company’s strategy to streamline its insulin offerings to cater to the growing needs of patients and to guarantee a consistent supply of medication, with a focus on newer treatment options. By retaining Mixtard in vial form, Novo Nordisk aims to ensure that patients in India have access to a reliable and effective insulin product.